NSC 146109 hydrochloride

Synonyms: XI-011 hydrochloride
NSC 146109 hydrochloride (XI-011 hydrochloride) 是一种 p53 激活剂和 MDMX 抑制剂,可抑制 MDMX 基因转录、下调 MDMX mRNA 和蛋白水平、稳定 p53 并激活 p53 的转录活性,进而诱导癌细胞凋亡 (apoptosis)、抑制转化细胞生长及异种移植瘤生长,可用于乳腺癌和宫颈癌的相关研究。
产品编号: MS-D56747 纯度: 99.89% CAS No.: 59474-01-0 分子式: C17H17ClN2S 分子量: 316.85
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

NSC 146109 hydrochloride (XI-011 hydrochloride) 是一种 p53 激活剂和 MDMX 抑制剂,可抑制 MDMX 基因转录、下调 MDMX mRNA 和蛋白水平、稳定 p53 并激活 p53 的转录活性,进而诱导癌细胞凋亡 (apoptosis)、抑制转化细胞生长及异种移植瘤生长,可用于乳腺癌和宫颈癌的相关研究。

生物实验数据

生物活性 NSC 146109 hydrochloride (XI-011 hydrochloride) is a p53 activator and MDMX inhibitor that inhibits MDMX gene transcription, downregulates MDMX mRNA and protein levels, stabilizes p53 and activates p53 transcriptional activity, thereby inducing apoptosis in cancer cells, inhibiting the growth of transformed cells and xenograft tumors, and can be used for research on breast cancer and cervical cancer.
体外研究
(In Vitro)

NSC 146109 hydrochloride (0-1 μM; 16 h) 可激活 MCF-7 细胞中的 p53、p21,上调 p53 靶基因的 mRNA (p21、PUMA、BAX、PIG3)。
NSC 146109 hydrochloride (0.5 μM; 16 h) 提高 MCF-7 细胞中 p53 蛋白的稳定性。
NSC 146109 hydrochloride (0-1 μM; 1-5 days) 可诱导 MCF-7 细胞发生凋亡,诱导呈剂量依赖性的 PARP 切割。
NSC 146109 hydrochloride (0-1 μM; 2-24 h) 可在 MCF-7 细胞中下调 MDMX 蛋白水平,激活 p53,抑制 MDMX 启动子活性,下调 MDMX mRNA 水平。
NSC 146109 hydrochloride (0-1 μM; 3-4 days) 可呈剂量依赖性降低野生型 p53 乳腺癌细胞 (MCF-7、ZR-75-1、ZR-75-30、MDA-MB-175VII) 的细胞活力,抑制 HeLa、Siha 和 Caski 人宫颈癌细胞的活力,其中对 HeLa 细胞的作用最强。
NSC 146109 hydrochloride (0.5-1.0 μM; 24 h) 显著抑制 HeLa、Siha 和 Caski 人宫颈癌细胞的长期集落形成。
NSC 146109 hydrochloride (0.5-1.0 μM; 24-72 h) 可时间和浓度依赖性地诱导 HeLa 细胞发生凋亡。
NSC 146109 hydrochloride (0.5-1.0 μM; 24 h) 可上调 HeLa、Siha 和 Caski 细胞中剪切型 PARP、p53、PUMA 及 p21 的蛋白水平,并下调 MDMX 的蛋白水平,提升 HeLa 细胞中 p53 蛋白的稳定性。
NSC 146109 hydrochloride (0.5-1.0 μM; 24 h) 可浓度依赖性地上调 HeLa 癌细胞中 p53 靶基因 PUMA、p21、BAX 和 PIG3 的 mRNA 表达。
NSC 146109 hydrochloride (0.5-1.0 μM; 72 h) 可显著增强 Cisplatin (MS-E94993) 对人宫颈癌细胞 HeLa 的细胞毒性。
NSC 146109 hydrochloride (0.5-1.0 μM; 24 h) 可增强 Cisplatin 诱导的人宫颈癌 HeLa 细胞中剪切型 PARP 和 p53 的表达升高,以及 MDMX 的表达降低。
NSC 146109 hydrochloride (0.5-1.0 μM) 可增强 Cisplatin 诱导的人宫颈癌细胞 HeLa 中 PUMA、p21、BAX 及 PIG3 的 mRNA 表达上调。

Western Blot Analysis

Cell Line: wild-type p53 MCF-7 breast cancer cells
Concentration: 0.1 μM, 0.2 μM, 0.5 μM, 1 μM
Incubation Time: 16 h
Result: Increased cellular p53 protein levels as efficiently as known p53 activators Nutlin-3a and RITA.
Caused a dose-dependent increase in p21 protein levels.

Real Time qPCR

Cell Line: wild-type p53 MCF-7 breast cancer cells
Concentration: 0.1 μM, 0.2 μM, 0.5 μM, 1.0 μM
Incubation Time: 16 h
Result: Induced dose-dependent increases in mRNA levels of the p53 target genes p21, PUMA, BAX, and PIG3, with statistically significant increases relative to DMSO control at all tested concentrations.
Achieved the greatest increase for PIG3, with a relative mRNA amount of 33.41 at 1.0 μM.

Western Blot Analysis

Cell Line: wild-type p53 MCF-7 breast cancer cells
Concentration: 0.5 μM (NSC 146109 pre-incubation); 100 μg/mL (Cycloheximide (MS-C76056))
Incubation Time: 16 h (NSC 146109 pre-incubation); 0-3 h (Cycloheximide)
Result: Extended the half-life of p53 protein significantly, as shown by sustained p53 levels over the 3-h Cycloheximide treatment period compared to the rapid decline in untreated control cells.

Cell Cycle Analysis

Cell Line: wild-type p53 MCF-7 breast cancer cells
Concentration: 0.5 μM
Incubation Time: 24 h, 48 h, 1-5 days
Result: Increased the sub-G0/G1 (apoptotic) cell population to 18.1% after 24 hours of treatment (from 2.04% in control).
Increased the sub-G0/G1 (apoptotic) cell population to 17.7% after 48 hours of treatment (from 1.76% in control).
Caused over 40% of MCF-7 cells to be apoptotic after 5 days of treatment, compared to less than 10% in DMSO control.

Apoptosis Analysis

Cell Line: wild-type p53 MCF-7 breast cancer cells
Concentration: 0.2 μM, 0.5 μM, 1.0 μM
Incubation Time: 48 h
Result: Caused a dose-dependent increase in TUNEL-positive apoptotic cells, with approximately 2% positive cells at 0.2 μM, 6% at 0.5 μM, and 7% at 1.0 μM, compared to less than 1% in DMSO control.

Western Blot Analysis

Cell Line: wild-type p53 MCF-7 breast cancer cells
Concentration: 0.1 μM, 0.2 μM, 0.5 μM, 1.0 μM
Incubation Time: 2 days
Result: Induced dose-dependent cleavage of PARP, a biochemical marker of apoptosis, with increasing levels of cleaved PARP seen at higher concentrations of the compound.

Western Blot Analysis

Cell Line: wild-type p53 MCF-7 breast cancer cells
Concentration: 0.1 μM, 0.25 μM, 0.5 μM, 1.0 μM (16 h incubation); 0.5 μM (time-course incubation)
Incubation Time: 16 h; 2-24 h
Result: Caused dose-dependent downregulation of MDMX protein levels, with concurrent dose-dependent upregulation of p53 and p21 protein levels.
Showed MDMX levels began decreasing 4-8 hours after treatment, coinciding with the onset of p53 activation.

Real Time qPCR

Cell Line: wild-type p53 MCF-7 breast cancer cells
Concentration: 0.1 μM, 0.2 μM, 0.5 μM
Incubation Time: 16 h
Result: Caused a dose-dependent decrease in MDMX mRNA levels, with relative mRNA level reduced to approximately 0.5 at 0.5 μM, compared to 1.0 in control.

Cell Viability Assay

Cell Line: wild-type p53 breast cancer cells (MCF-7, ZR-75-1, ZR-75-30, MDA-MB-175VII)
Concentration: 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1.0 μM
Incubation Time: 4 days
Result: Caused a dose-dependent decrease in cell viability in all tested cell lines.
Reduced viability to ~10% at 1.0 μM in MCF-7 cells (high MDMX expression).
Left viabilities at ~20%, ~40%, and ~20% respectively at 1.0 μM in ZR-75-1, ZR-75-30, and MDA-MB-175VII cells (low MDMX expression).

Cell Viability Assay

Cell Line: HeLa, Siha, Caski human cervical cancer cells
Concentration: 0, 0.1, 1, 10, 100 μM
Incubation Time: 72 h
Result: Dose-dependently reduced cell viability in all three cervical cancer cell lines, with the highest proliferation inhibition observed in HeLa cells.
体内研究
(In Vivo)

NSC 146109 hydrochloride 负载脂质体 (10 mg/kg;腹腔注射;每周 3 次;共 18 天) 可抑制 BALB/c-nude 小鼠体内 HeLa 细胞异种移植瘤的生长,肿瘤生长抑制率达 49.2%。

Animal Model: BALB/c-nude (female, 6-7 weeks old, subcutaneous HeLa cell xenograft)
Dosage: 10 mg/kg
Administration: i.p.; three times a week; 18 days
Result: Reduced mean tumor weight to 0.41 g.
Achieved a tumor growth inhibition rate of 49.2%.
Significantly reduced tumor volume relative to control.
Caused no apparent toxicity in treated mice.
性状 固体
颜色 White to yellow

化学信息

分子量 316.85
分子式 C17H17ClN2S
CAS No. 59474-01-0
别名 XI-011 hydrochloride

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (10.42 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 83.33 mg/mL (263.00 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.1561 mL15.7803 mL31.5607 mL78.9017 mL
5 mM0.6312 mL3.1561 mL6.3121 mL15.7803 mL
10 mM0.3156 mL1.5780 mL3.1561 mL7.8902 mL
15 mM0.2104 mL1.0520 mL2.1040 mL5.2601 mL
20 mM0.1578 mL0.7890 mL1.5780 mL3.9451 mL
25 mM0.1262 mL0.6312 mL1.2624 mL3.1561 mL
30 mM0.1052 mL0.5260 mL1.0520 mL2.6301 mL
40 mM0.0789 mL0.3945 mL0.7890 mL1.9725 mL
50 mM0.0631 mL0.3156 mL0.6312 mL1.5780 mL
60 mM0.0526 mL0.2630 mL0.5260 mL1.3150 mL
80 mM0.0395 mL0.1973 mL0.3945 mL0.9863 mL
100 mM0.0316 mL0.1578 mL0.3156 mL0.7890 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础